Phaseline

Companies › Inozyme Pharma

Inozyme Pharma: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 1 Phase 3, 1 Phase 2, 1 Phase 1; Metabolic and endocrine.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
INZ-701
Recombinant ENPP1-Fc fusion protein
ENPP1Phase 3Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency; Gene Mutations; Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06046820INZ-701Phase 3Ectonucleotide Pyrophosphatase/Phosphodiesterase1 DeficiencyMetabolic and endocrineJan 2026
NCT05734196INZ-701Phase 1Ectonucleotide Pyrophosphatase/phosphodiesterase1 DeficiencyMetabolic and endocrineSep 2026
NCT06462547INZ-701Phase 2Gene MutationsMetabolic and endocrineSep 2026

Targets

ENPP1 (1)

Companies with the same targets

Riboscience Colgate Palmolive Stingray Therapeutics

Companies built like this

BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. Xintian Pharmaceutical Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Orphalan Lumos Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.